The United States Patent and Trademark Office has granted US patent No. 10376465 (“Monovalent Metal Cation Dry Powders for Inhalation”) to Pulmatrix, the company said. The claims cover formulations of Pulmazole inhaled dry powder itraconazole, which is based on Pulmatrix’s iSPERSE particle engineering technology. Earlier this year, Pulmatrix announce that it had received five new patents for other iSPERSE formulations in its pipeline.
In July 2019, the company initiated a Phase 2 trial of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma shortly after licensing the Pulmazole DPI to Cip Tec for that indication.
Pulmatrix CEO Ted Raad commented, “The expansion of our iSPERSE intellectual property rights in the United States builds upon our growing worldwide patent estate supporting our platform technology and our proprietary programs. This patent is a valuable step in supporting the development of our lead anti-fungal program to serve unmet needs of patients worldwide.”
Read the Pulmatrix press release.
